India markets closed
  • BSE SENSEX

    39,614.07
    -135.78 (-0.34%)
     
  • Nifty 50

    11,642.40
    -28.40 (-0.24%)
     
  • USD/INR

    74.6040
    +0.2140 (+0.29%)
     
  • Dow

    26,188.38
    -470.73 (-1.77%)
     
  • Nasdaq

    10,841.94
    -343.65 (-3.07%)
     
  • BTC-INR

    1,007,256.00
    +19,384.50 (+1.96%)
     
  • CMC Crypto 200

    263.81
    +0.18 (+0.07%)
     
  • Hang Seng

    24,107.42
    -479.18 (-1.95%)
     
  • Nikkei

    22,977.13
    -354.81 (-1.52%)
     
  • EUR/INR

    86.9117
    +0.0346 (+0.04%)
     
  • GBP/INR

    96.6229
    +0.4725 (+0.49%)
     
  • AED/INR

    20.2670
    +0.0580 (+0.29%)
     
  • INR/JPY

    1.3999
    -0.0036 (-0.26%)
     
  • SGD/INR

    54.6220
    +0.1690 (+0.31%)
     

Albuterol Boost comes in for Cipla & Lupin; Perrigo’s exit to benefit both?

The market is clearly all about the pharma today. Apart from DRL and the big boost that it has received today, Cipla and Lupin continue to be amongst the top stocks.

Albuterol Boost comes in for Cipla, and it came in the month of April and they have got 10%+ market share and Lupin got the approval very recently. Lupin seems to have got the batches as what has been told by the company to ET Now. Perrigo which is one of the important players has gone ahead and withdrawn the drug.

According to the analysts, Cipla &Lupin are already in the market with Albuterol and that this is an opportunity to gain till Perrigo comes back